Brown, Lisle/Cummings, Inc. Bio N Tech Se Transaction History
Brown, Lisle/Cummings, Inc.
- $345 Billion
- Q1 2025
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 11 shares of BNTX stock, worth $1,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11Holding current value
$1,122% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
363Shares Held
39.6MCall Options Held
3.01MPut Options Held
2.01M-
Baillie Gifford & CO8.22MShares$839 Million0.74% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.41MShares$450 Million2.03% of portfolio
-
Primecap Management CO Pasadena, CA4.3MShares$438 Million0.39% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$193 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$184 Million1.03% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $24.8B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...